80 related articles for article (PubMed ID: 20196631)
1. Microencapsulation of sodium alendronate reduces drug mucosal damage in rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Guterres SS; Pohlmann AR
Drug Deliv; 2010 May; 17(4):231-7. PubMed ID: 20196631
[TBL] [Abstract][Full Text] [Related]
2. Gastroresistant microparticles containing sodium alendronate prevent the bone loss in ovariectomized rats.
Cruz L; Assumpção E; Andrade SF; Conrado DJ; Kulkamp IC; Guterres SS; Pohlmann AR
Eur J Pharm Sci; 2010 Aug; 40(5):441-7. PubMed ID: 20471479
[TBL] [Abstract][Full Text] [Related]
3. Gastroprotective effect of leukotriene receptor blocker montelukast in alendronat-induced lesions of the rat gastric mucosa.
Sener G; Kapucu C; Cetinel S; Cikler E; Ayanoğlu-Dülger G
Prostaglandins Leukot Essent Fatty Acids; 2005 Jan; 72(1):1-11. PubMed ID: 15589394
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of taurine against alendronate-induced gastric damage in rats.
Sener G; Sehirli O; Cetinel S; Midillioğlu S; Gedik N; Ayanoğlu-Dülger G
Fundam Clin Pharmacol; 2005 Feb; 19(1):93-100. PubMed ID: 15660965
[TBL] [Abstract][Full Text] [Related]
5. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery.
Cruz L; Fattal E; Tasso L; Freitas GC; Carregaro AB; Guterres SS; Pohlmann AR; Tsapis N
J Control Release; 2011 Jun; 152(3):370-5. PubMed ID: 21396412
[TBL] [Abstract][Full Text] [Related]
6. Alendronate-loaded microparticles for improvement of intestinal cellular absorption.
Baek JS; Kwon HH; Hwang JS; Sung HC; Lee JM; Shin SC; Kim YR; Cho CW
J Drug Target; 2011 Jan; 19(1):37-48. PubMed ID: 20477555
[TBL] [Abstract][Full Text] [Related]
7. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
[TBL] [Abstract][Full Text] [Related]
8. pH-dependent release of platycodin mitigates its gastrointestinal mucosa irritation after oral administration in rats.
Chen Q; Yang WW; Shen P; Cao QR; Lee BJ; Cui JH
Arch Pharm Res; 2016 Jun; 39(6):811-24. PubMed ID: 27241507
[TBL] [Abstract][Full Text] [Related]
9. Development of HPMC and Eudragit S100 blended microparticles containing sodium pantoprazole.
Raffin RP; Colomé LM; Haas SE; Jornada DS; Pohlmann AR; Guterres SS
Pharmazie; 2007 May; 62(5):361-4. PubMed ID: 17557744
[TBL] [Abstract][Full Text] [Related]
10. Ghrelin against alendronate-induced gastric damage in rats.
Işeri SO; Sener G; Yüksel M; Contuk G; Cetinel S; Gedik N; Yegen BC
J Endocrinol; 2005 Dec; 187(3):399-406. PubMed ID: 16423819
[TBL] [Abstract][Full Text] [Related]
11. Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate.
Kanatsu K; Aihara E; Okayama M; Kato S; Takeuchi K
J Gastroenterol Hepatol; 2004 May; 19(5):512-20. PubMed ID: 15086594
[TBL] [Abstract][Full Text] [Related]
12. Octreotide ameliorates alendronate-induced gastric injury.
Sener G; Paskaloglu K; Kapucu C; Cetinel S; Contuk G; Ayanoğlu-Dülger G
Peptides; 2004 Jan; 25(1):115-21. PubMed ID: 15003363
[TBL] [Abstract][Full Text] [Related]
13. Effects of alendronate on gastric and duodenal mucosa.
Lanza F; Rack MF; Simon TJ; Lombardi A; Reyes R; Suryawanshi S
Am J Gastroenterol; 1998 May; 93(5):753-7. PubMed ID: 9625122
[TBL] [Abstract][Full Text] [Related]
14. Upper gastrointestinal toxicity of alendronate.
Lowe CE; Depew WT; Vanner SJ; Paterson WG; Meddings JB
Am J Gastroenterol; 2000 Mar; 95(3):634-40. PubMed ID: 10710050
[TBL] [Abstract][Full Text] [Related]
15. Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery.
Kendall RA; Alhnan MA; Nilkumhang S; Murdan S; Basit AW
Eur J Pharm Sci; 2009 Jun; 37(3-4):284-90. PubMed ID: 19491017
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of gastric toxicity of indomethacin acid, salt form and complexed forms with hydroxypropyl-beta-cyclodextrin on Wistar rats: histopathologic analysis.
Ribeiro-Rama AC; Figueiredo IV; Veiga F; Castel-Branco MM; Cabrita AM; Caramona MM
Fundam Clin Pharmacol; 2009 Dec; 23(6):747-55. PubMed ID: 19656206
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
Vachal P; Hale JJ; Lu Z; Streckfuss EC; Mills SG; MacCoss M; Yin DH; Algayer K; Manser K; Kesisoglou F; Ghosh S; Alani LL
J Med Chem; 2006 Jun; 49(11):3060-3. PubMed ID: 16722624
[TBL] [Abstract][Full Text] [Related]
18. Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.
Graham DY; Malaty HM; Goodgame R
Am J Gastroenterol; 1997 Aug; 92(8):1322-5. PubMed ID: 9260798
[TBL] [Abstract][Full Text] [Related]
19. Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds.
Scarpignato C; Pelosini I
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S63-72. PubMed ID: 10379472
[TBL] [Abstract][Full Text] [Related]
20. Sucralfate protection against gastrointestinal damage: possible role of prostanoids.
Ligumsky M; Karmeli F; Rachmilewitz D
Isr J Med Sci; 1986 Nov; 22(11):801-6. PubMed ID: 3098700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
